5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Treatment and Outcomes of Infections Caused by Diverse Carbapenemase-Producing Carbapenem-Resistant Enterobacterales

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Diverse sequence types (ST) and various carbapenemase-producing carbapenem-resistant Enterobacterales (CP-CRE) infections, which complicate treatment strategies, have emerged in Singapore. We aim to describe these CP-CRE infections and clinical outcomes according to their carbapenemase types and determine the hierarchy of predictors for mortality that are translatable to clinical practice.

          Methods: Clinically significant CP-CRE infections were identified in Singapore General Hospital between 2013 and 2016. Retrospectively, all clinically relevant data were retrieved from electronic medical records from the hospital. Univariate analysis was performed. To further explore the relationship between the variables and mortality in different subsets of patients with CP-CRE, we conducted recursive partitioning analysis on all study variables using the “rpart” package in R.

          Results: One hundred and fifty five patients were included in the study. Among them, 169 unique CP-CRE were isolated. Thirty-day all-cause in-hospital mortality was 35.5% ( n = 55). There was no difference in the severity of illness, or any clinical outcomes exhibited by patients between the various carbapenemases. Root node began with patients with Acute Physical and Chronic Health Evaluation (APACHEII) score ≥ 15 ( n = 98; mortality risk = 52.0%) and <15 ( n = 57; mortality risk = 9.0%). Patients with APACHEII score ≥ 15 are further classified based on presence ( n = 27; mortality risk = 23.0%) and absence ( n = 71, mortality risk = 62.0%) of bacterial eradication. Without bacterial eradication, absence ( n = 54) and presence ( n = 17) of active source control yielded 70.0 and 35.0% mortality risk, respectively. Without active source control, the mortality risk was higher for the patients with non-receipt of definite combination therapy ( n = 36, mortality risk = 83.0%) when compared to those who received ( n = 18, mortality risk = 47.0%). Overall, the classification tree has an area under receiver operating characteristic curve of 0.92, with a sensitivity of 0.87 and specificity of 0.91.

          Conclusion: Different mortality risks were observed with different treatment strategies. Effective source control and microbial eradication were associated with a lower mortality rate but not active empiric therapy for CP-CRE infection. When source control was impossible, definitive antibiotic combination appeared to be associated with a reduction in mortality.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

          The objective of this study was to develop a prospectively applicable method for classifying comorbid conditions which might alter the risk of mortality for use in longitudinal studies. A weighted index that takes into account the number and the seriousness of comorbid disease was developed in a cohort of 559 medical patients. The 1-yr mortality rates for the different scores were: "0", 12% (181); "1-2", 26% (225); "3-4", 52% (71); and "greater than or equal to 5", 85% (82). The index was tested for its ability to predict risk of death from comorbid disease in the second cohort of 685 patients during a 10-yr follow-up. The percent of patients who died of comorbid disease for the different scores were: "0", 8% (588); "1", 25% (54); "2", 48% (25); "greater than or equal to 3", 59% (18). With each increased level of the comorbidity index, there were stepwise increases in the cumulative mortality attributable to comorbid disease (log rank chi 2 = 165; p less than 0.0001). In this longer follow-up, age was also a predictor of mortality (p less than 0.001). The new index performed similarly to a previous system devised by Kaplan and Feinstein. The method of classifying comorbidity provides a simple, readily applicable and valid method of estimating risk of death from comorbid disease for use in longitudinal studies. Further work in larger populations is still required to refine the approach because the number of patients with any given condition in this study was relatively small.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Regression Shrinkage and Selection Via the Lasso

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

              Many different definitions for multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) bacteria are being used in the medical literature to characterize the different patterns of resistance found in healthcare-associated, antimicrobial-resistant bacteria. A group of international experts came together through a joint initiative by the European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC), to create a standardized international terminology with which to describe acquired resistance profiles in Staphylococcus aureus, Enterococcus spp., Enterobacteriaceae (other than Salmonella and Shigella), Pseudomonas aeruginosa and Acinetobacter spp., all bacteria often responsible for healthcare-associated infections and prone to multidrug resistance. Epidemiologically significant antimicrobial categories were constructed for each bacterium. Lists of antimicrobial categories proposed for antimicrobial susceptibility testing were created using documents and breakpoints from the Clinical Laboratory Standards Institute (CLSI), the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the United States Food and Drug Administration (FDA). MDR was defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories, XDR was defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories (i.e. bacterial isolates remain susceptible to only one or two categories) and PDR was defined as non-susceptibility to all agents in all antimicrobial categories. To ensure correct application of these definitions, bacterial isolates should be tested against all or nearly all of the antimicrobial agents within the antimicrobial categories and selective reporting and suppression of results should be avoided. © 2011 European Society of Clinical Microbiology and Infectious Diseases. No claim to original US government works.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Cell Infect Microbiol
                Front Cell Infect Microbiol
                Front. Cell. Infect. Microbiol.
                Frontiers in Cellular and Infection Microbiology
                Frontiers Media S.A.
                2235-2988
                14 October 2020
                2020
                : 10
                : 579462
                Affiliations
                [1] 1Department of Pharmacy, Singapore General Hospital , Singapore, Singapore
                [2] 2Department of Pharmacy, National University of Singapore , Singapore, Singapore
                [3] 3Saw Swee Hock School of Public Health, National University of Singapore , Singapore, Singapore
                [4] 4Department of Infectious Diseases, Singapore General Hospital , Singapore, Singapore
                [5] 5Emerging Infectious Diseases Programme, Duke-National University of Singapore Medical School , Singapore, Singapore
                [6] 6Singhealth Duke-National University of Singapore Medical School, Medicine Academic Clinical Programme , Singapore, Singapore
                Author notes

                Edited by: Maria Teresa Mascellino, Sapienza University of Rome, Italy

                Reviewed by: Pascale Vonaesch, Swiss Tropical and Public Health Institute (Swiss TPH), Switzerland; Krisztina M. Papp-Wallace, Louis Stokes Cleveland VA Medical Center, United States

                *Correspondence: Andrea L. H. Kwa andrea.kwa.l.h@ 123456sgh.com.sg

                This article was submitted to Clinical Microbiology, a section of the journal Frontiers in Cellular and Infection Microbiology

                †These authors have contributed equally to this work

                ‡ORCID: Andrea L. H. Kwa orcid.org/0000-0001-8981-4411

                Article
                10.3389/fcimb.2020.579462
                7591786
                33178629
                062c6dd7-5a2d-4193-a86c-b4e91bd6bb19
                Copyright © 2020 Lim, Liew, Cai, Lee, Teo, Lay, Chung and Kwa.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 02 July 2020
                : 28 August 2020
                Page count
                Figures: 2, Tables: 6, Equations: 0, References: 43, Pages: 11, Words: 7413
                Funding
                Funded by: National Medical Research Council 10.13039/501100001349
                Categories
                Cellular and Infection Microbiology
                Original Research

                Infectious disease & Microbiology
                treatment,outcomes,infections,carbapenemase-producing,carbapenem-resistance,enterobacterales

                Comments

                Comment on this article